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In Figure 5 of this paper, the FACS events (dots) were inadvertently lost in the right-hand panel (panel 4, B*57 116 Ser-Tyr) during the
preparation of the revised manuscript. The complete Figure 5 is reproduced here. The authors regret this error.
Figure 5. Fine Specificity of Abacavir-Specific CD8+ T Cells Determined by the Antigen-Binding F Pocket
Abacavir-specific T cells were raised in vitro from a HLA-B*5701-positive donor and then restimulated with the C1R cell lines expressing HLA-B*5701,
HLAB*5703, the HLA-B*5703 back mutant 114Asp/Asn, or the HLA-B*5703 back mutant 116Ser/Tyr. Flow histograms of gated lymphocytes are shown
stained for intracellular IFNg (y axis) and CD8 (x axis). The percentage of responding IFNg+ CD8+ T cells as a fraction of total gated lymphocytes is shown in
the upper-right-hand quadrants. Differences between the peptide-binding clefts of HLA-B*5701, HLA-B*5703, and HLA-B*5703 back mutants are indicated
with filled circles, and the amino acid substitutions from B*5701 are given above each illustration.Immunity 29, 165, July 18, 2008 ª2008 Elsevier Inc. 165
